GCM
TEVA icon

Gunpowder Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Gunpowder Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$949 Hold
28
– – ﹤0.01% 370
2026
Q1 		$843 Hold
28
– – ﹤0.01% 373
2025
Q4 		$873 Buy
+28
New +$690 ﹤0.01% 396

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Gunpowder Capital Management's TEVA Position: Q2 2026 in Review

Gunpowder Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 28 shares worth $949. The position accounts for ﹤0.01% of the portfolio, ranked #370.

Gunpowder Capital Management first reported a position in TEVA in Q4 2025 and has held it in 3 quarters since. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Gunpowder Capital Management held 28 shares of Teva Pharmaceuticals worth $949 as of Q2 2026.
  • Gunpowder Capital Management left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Gunpowder Capital Management's portfolio in Q2 2026, its #370 holding.
  • Gunpowder Capital Management first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Gunpowder Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.